What is the best way to measure renal fibrosis¿: A pathologist's perspective

Kidney International Supplements

Volumn 4, Issue 1, 2014, Pages 9-15

  Farris, Alton B ^a   Alpers, Charles E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

collagen; fibrosis; interstitial fibrosis; morphometry; picrosirius red; trichrome stain

Indexed keywords

HISTOPATHOLOGY; HUMAN; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MICROVASCULATURE; PATHOLOGIST; REVIEW; VASCULARIZATION;

EID: 84908499515     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2014.3     Document Type: Short Survey

References (97)

1. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
2. Zeisberg EM, Potenta SE, Sugimoto H et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287.
3. Zeisberg M, Kalluri R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci 2008; 13: 6991-6998.
4. Kaissling B, Le Hir M. The renal cortical interstitium: morphological and functional aspects. Histochem Cell Biol 2008; 130: 247-262.
5. Christensen EI, Verroust PJ. Interstitial fibrosis: tubular hypothesis versus glomerular hypothesis. Kidney Int 2008; 74: 1233-1236.
6. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
7. Racusen LC, Solez K, Colvin R. Fibrosis and atrophy in the renal allograft: interim report and new directions. Am J Transplant 2002; 2: 203-206.
8. Farris AB, Colvin RB. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012; 21: 289-300.
9. Grimm PC, Nickerson P, Gough J et al. Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant 1999; 3: 257-270.
10. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
11. Choi BS, Shin MJ, Shin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354-1360.
12. Colvin RB, Nickeleit V. Renal transplant pathology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall's Pathology of the Kidney 6th edn, vol. 2. Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2006 pp 1347-1490.
13. Cosio FG, Grande JP, Wadei H et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
14. Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
15. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009; 5: 375-383.
16. Boor P, Sebekova K, Ostendorf T et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22: 3391-3407.
17. Austin HA 3rd, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
18. Alpers CE, Hudkins KL, Floege J et al. Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994; 5: 201-209.
19. Humphreys BD, Lin SL, Kobayashi A et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
20. Hunter MG, Hurwitz S, Bellamy CO et al. Quantitative morphometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate. Kidney Int 2005; 67: 94-102.
21. Clapp WL, Croker BP. Kidney. In: Mills SE (ed) Histology for Pathologists, 3rd edn, Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.
22. Hestbech J, Hansen HE, Amdisen A et al. Chronic renal lesions following long-term treatment with lithium. Kidney Int 1977; 12: 205-213.
23. Bohle A, Grund KE, Mackensen S et al. Correlations between renal interstitium and level of serum creatinine. Morphometric investigations of biopsies in perimembranous glomerulonephritis. Virchows Arch A Pathol Anat Histol 1977; 373: 15-22.
24. Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex. A quantitative study. Virchows Arch A Pathol Anat Histol 1980; 387: 271-277.
25. Bonsib SM. Renal anatomy and histology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall's Pathology of the Kidney, 6th edn, Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.
26. Wall SM, Truong AV, DuBose TD Jr. H(+)-K(+)-ATPase mediates net acid secretion in rat terminal inner medullary collecting duct. Am J Physiol 1996; 271: F1037-F1044.
27. Stokes MB, Holler S, Cui Y et al. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int 2000; 57: 487-498.
28. Mounier F, Foidart JM, Gubler MC. Distribution of extracellular matrix glycoproteins during normal development of human kidney. An immunohistochemical study. Lab Invest 1986; 54: 394-401.
29. Karkavelas G, Kefalides NA, Amenta PS et al. Comparative ultrastructural localization of collagen types III, IV, VI and laminin in rat uterus and kidney. J Ultrastruct Mol Struct Res 1988; 100: 137-155.
30. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656.
31. Dussaule JC, Guerrot D, Huby AC et al. The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol 2011; 92: 151-157.
32. Meran S, Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 2011; 92: 158-167.
33. Ru Y, Eyden B. The ultrastructure of human tubulo-interstitial fibrosis. J Submicrosc Cytol Pathol 2003; 35: 147-160.
34. Tapmeier TT, Fearn A, Brown K et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int 2010; 78: 351-362.
35. Nikolic-Paterson DJ. CD4+ T cells: a potential player in renal fibrosis. Kidney Int 2010; 78: 333-335.
36. Snelgrove SL, Kausman JY, Lo C et al. Renal dendritic cells adopt a pro-inflammatory phenotype in obstructive uropathy to activate T cells, but do not directly contribute to fibrosis. Am J Pathol 2011; 180: 91-103.
37. Lin SL, Castano AP, Nowlin BT et al. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009; 183: 6733-6743.
38. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925.
39. Machida Y, Kitamoto K, Izumi Y et al. Renal fibrosis in murine obstructive nephropathy is attenuated by depletion of monocyte lineage, not dendritic cells. J Pharmacol Sci 2010; 114: 464-473.
40. Pilling D, Fan T, Huang D et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 2009; 4: e7475.
41. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semin Nephrol 2010; 30: 302-317.
42. Semedo P, Donizetti-Oliveira C, Burgos-Silva M et al. Bone marrow mononuclear cells attenuate fibrosis development after severe acute kidney injury. Lab Invest 2010; 90: 685-695.
43. Olagne J, Caillard S, Gaub MP et al. Post-transplant lymphoproliferative disorders: determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11: 1260-1269.
44. Kurts C, Heymann F, Lukacs-Kornek V et al. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol 2007; 29: 317-335.
45. Macconi D, Chiabrando C, Schiarea S et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 2009; 20: 123-130.
46. Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009; 119: 1286-1297.
47. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858-862.
48. Kanamaru Y, Scandiuzzi L, Essig M et al. Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J Immunol 2006; 176: 5607-5615.
49. Veerappan A, Reid AC, O'Connor N et al. Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol 2012; 302: F192-F204.
50. Niedermeier M, Reich B, Rodriguez Gomez M et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
51. Sakai N, Furuichi K, Shinozaki Y et al. Fibrocytes are involved in the pathogenesis of human chronic kidney disease. Hum Pathol 2010; 41: 672-678.
52. Shao DD, Suresh R, Vakil V et al. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-1333.
53. Broekema M, Harmsen MC, van Luyn MJ et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007; 18: 165-175.
54. Lin SL, Kisseleva T, Brenner DA et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
55. Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006; 2: 398-404.
56. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl 2003; S105-S112.
57. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
58. Farris AB, Lawson D, Cohen C et al. Medullary injury in the human renal biopsy: fibrosis assessment. Mod Pathol 2013; 26: 387A-388A.
59. Steegh FM, Gelens MA, Nieman FH et al. Early loss of peritubular capillaries after kidney transplantation. J Am Soc Nephrol 2011; 22: 1024-1029.
60. Moreso F, Lopez M, Vallejos A et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 82-88.
61. Marcussen N, Olsen TS, Benediktsson H et al. Reproducibility of the Banff classification of renal allograft pathology. Inter- and intraobserver variation. Transplantation 1995; 60: 1083-1089.
62. Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int 2001; 60: 1998-2012.
63. Furness PN, Taub N, Assmann KJ et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805-810.
64. Farris AB, Adams CD, Brousaides N et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2011; 22: 176-186.
65. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979; 11: 447-455.
66. Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 1662-1668.
67. Sund S, Grimm P, Reisaeter AV et al. Computerized image analysis vs semiquantitative scoring in evaluation of kidney allograft fibrosis and prognosis. Nephrol Dial Transplant 2004; 19: 2838-2845.
68. Servais A, Meas-Yedid V, Buchler M et al. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation 2007; 84: 1595-1601.
69. Servais A, Meas-Yedid V, Toupance O et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
70. Feldman DL, Mogelesky TC, Chou M et al. Enhanced expression of renal endothelin-converting enzyme-1 and endothelin-A-receptor mRNA in rats with interstitial fibrosis following ureter ligation. J Cardiovasc Pharmacol 2000; 36: S255-S259.
71. Satoh M, Kashihara N, Yamasaki Y et al. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2001; 12: 317-325.
72. Nicholson ML, Bailey E, Williams S et al. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236-241.
73. Moreso F, Seron D, Vitria J et al. Quantification of interstitial chronic renal damage by means of texture analysis. Kidney Int 1994; 46: 1721-1727.
74. De Heer E, Sijpkens YW, Verkade M et al. Morphometry of interstitial fibrosis. Nephrol Dial Transplant 2000; 15(Suppl 6): 72-73.
75. Celik B, Randhawa PS. Glomerular changes in BK virus nephropathy. Hum Pathol 2004; 35: 367-370.
76. Meas-Yedid V, Servais A, Noel LH et al. New computerized color image analysis for the quantification of interstitial fibrosis in renal transplantation. Transplantation 2011; 92: 890-899.
77. Miura Y, Satoh S, Saito M et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 2011; 91: 78-85.
78. Pape L, Mengel M, Offner G et al. Renal arterial resistance index and computerized quantification of fibrosis as a combined predictive tool in chronic allograft nephropathy. Pediatr Transplant 2004; 8: 565-570.
79. Pape L, Henne T, Offner G et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76: 955-958.
80. Farris AB, Chan S, Climenhaga J et al. Banff fibrosis study: multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant 2014; 14: 897-907.
81. Sigdel S, Gemind JT, Tomashefski JF Jr. The Movat pentachrome stain as a means of identifying microcrystalline cellulose among other particulates found in lung tissue. Arch Pathol Lab Med 2011; 135: 249-254.
82. Maluf DG, Mas VR, Archer KJ et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med 2008; 14: 276-285.
83. Bunnag S, Einecke G, Reeve J et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20: 1149-1160.
84. Sethi S, Vrana JA, Theis JD et al. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 273-280.
85. Austin HA 3rd, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
86. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
87. Mengel M, Sis B, Haas M et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
88. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
89. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562-1566.
90. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
91. Sis B, Mengel M, Haas M et al. Banff '09 Meeting Report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
92. Solez K. History of the Banff classification of allograft pathology as it approaches its 20th year. Curr Opin Organ Transplant 2010; 15: 49-51.
93. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
94. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760.
95. Fogo AB, Bostad L, Svarstad E et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25: 2168-2177.
96. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
97. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563.